ImmuPharma (IMM) AI Stock Analysis

• Market Cap: £27.20M
• Dividend Yield: N/A
• Average Volume (3M): 15.00M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 502,723,940
• 10 Day Avg. Volume: 4,827,745
• 30 Day Avg. Volume: 14,996,625
• PEG Ratio: 0.08
• Price to Book (P/B): -9.23
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: 6.00 p ▼(-3.23% Downside)
• Action: Reiterated Date: 01/08/26
• Date: Action: Reiterated 01/08/26

The score is weighed down primarily by very weak financial performance (near-zero revenue, persistent losses, ongoing cash burn, and negative equity). Technicals are mixed but modestly supportive versus the 200-day average, while valuation remains challenged due to losses and the absence of dividend yield.

Positive Factors

Low leverage / minimal debt

Near-zero reported debt reduces fixed interest costs and financial distress risk, preserving flexibility. For a clinical-stage biotech this allows management to prioritize R&D and partner negotiations without immediate debt servicing constraints, supporting longer-term program funding options.

Improving operating losses

Narrowing losses vs prior years indicates disciplined cost control and more efficient program spending. This trend lengthens runway per unit of funding, increases the chance of reaching clinical or partnering milestones before additional dilutive financings are required, a durable operational improvement.

Partnership/licensing business model

A partnering-centric model lets the company de‑risk late-stage development and commercialization by leveraging partner scale and capital. Structurally, this enables capital-efficient progress of candidates and potential milestone/royalty upside without building large commercial infrastructure.

Negative Factors

Absent recurring revenue

A near-zero revenue base removes any recurring cash cushion and makes the company wholly dependent on milestone, partner payments or financings. This structurally limits self‑funding capacity and increases execution risk if anticipated transactions or partnerships do not materialize.

Negative shareholders' equity

Negative equity signals accumulated losses and a weakened balance sheet, reducing borrowing capacity and counterparties' confidence. Over months this can constrain strategic options, increase cost of capital, and force more dilutive financings to sustain R&D and operations.

Persistent cash burn

Consistent negative operating and free cash flow requires external funding to continue development programs. Structurally, ongoing burn increases dilution risk, can delay or curtail trials if funding gaps occur, and places pressure on management to secure partnerships or financing on favorable terms.

ImmuPharma Business Overview & Revenue Model

Company Description

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

How the Company Makes Money

ImmuPharma’s primary way of generating revenue is through the business model typical of clinical-stage biopharmaceutical companies: progressing proprietary drug candidates and seeking monetization via partnering and transaction-based income rather than broad, recurring product sales. Key potential revenue streams include (1) licensing and partnering deals in which it grants rights to develop and/or commercialize a drug candidate in exchange for upfront payments, development and regulatory milestone payments, and future royalties on sales; and (2) other collaboration-related receipts where a counterparty funds certain development activities (the availability and materiality of such arrangements for ImmuPharma is null). If the company has approved products on the market, revenue could also come from direct product sales or profit-sharing arrangements, but specific evidence of current marketed-product revenue is null. As a development-focused company, its reported income (when present) is often driven by the timing of partner payments and transactions, while ongoing operations are typically supported by equity financings; however, the extent to which financing contributes to reported revenue is null because financing proceeds are not operating revenue and company-specific details are not provided here.

ImmuPharma Financial Statement Overview

Summary

Financials are very weak: revenue is effectively zero, losses persist (2024 net loss ~£2.5m), and operating/free cash flow remain negative (~-£1.8m in 2024). While debt is essentially zero, equity turned negative in 2024 and total assets have declined, reducing financial flexibility and increasing reliance on future funding.

Income Statement

Operating performance remains very weak. Revenue is effectively zero in 2022–2024 (down -100% in 2024), while losses persist (2024 net loss of ~£2.5m; EBIT and EBITDA also deeply negative). Losses have narrowed versus 2021–2022, but the absence of a meaningful revenue base keeps profitability and earnings quality highly challenged.

Balance Sheet

Leverage is low (reported debt essentially zero), which is a positive. However, the balance sheet has deteriorated materially: stockholders’ equity turned negative in 2024 (from positive in 2023), signaling accumulated losses and reduced financial flexibility. Total assets have also declined meaningfully from 2020–2024, highlighting balance-sheet contraction despite minimal debt burden.

Cash Flow

Cash generation is consistently negative, with operating cash flow and free cash flow remaining cash-burn each year (2024 operating cash flow ~-£1.8m; free cash flow ~-£1.8m). The burn rate improved versus 2021–2022, but cash flow remains structurally negative and reliant on external funding or balance-sheet resources; free cash flow trends are volatile and still below zero.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	118.35K	126.67K
Gross Profit	-73.56K	-63.88K	-37.61K	-118.00K	118.35K	126.67K
EBITDA	-3.07M	-2.61M	-3.02M	-2.91M	-8.70M	-6.84M
Net Income	-3.93M	-2.48M	-2.92M	-3.81M	-8.17M	-6.86M
Balance Sheet
Total Assets	1.58M	977.01K	2.72M	3.97M	6.00M	10.92M
Cash, Cash Equivalents and Short-Term Investments	396.65K	236.90K	208.48K	667.81K	1.65M	5.86M
Total Debt	0.00	0.00	0.00	111.00	700.00	641.84K
Total Liabilities	1.24M	1.52M	1.67M	1.45M	1.58M	1.26M
Stockholders Equity	336.70K	-542.86K	1.06M	2.52M	4.41M	9.65M
Cash Flow
Free Cash Flow	-1.90M	-1.77M	-1.36M	-2.45M	-4.88M	-3.69M
Operating Cash Flow	-1.90M	-1.77M	-1.36M	-2.35M	-4.83M	-3.33M
Investing Cash Flow	-273.37K	1.29M	188.76K	-77.42K	-50.28K	-569.20K
Financing Cash Flow	2.09M	500.02K	722.10K	1.55M	702.05K	8.37M

ImmuPharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
POLB	49 Neutral	£29.97M	-1.92	-53.86%	―	―	―
SCLP	48 Neutral	£132.32M	-4.45	90.29%	―	―	-94.12%
HEMO	47 Neutral	£71.48M	-0.27	-3931.14%	―	―	―
IMM	46 Neutral	£27.20M	-3.00	3817.30%	―	―	―
SAR	44 Neutral	£21.40M	-3.13	-202.14%	―	―	23.76%
SBTX	43 Neutral	£27.21M	-54.98	-10.01%	―	283.74%	78.57%

ImmuPharma Corporate Events

ImmuPharma Launches £1.5m WRAP Retail Share Offer Alongside £7.5m Subscription

ImmuPharma has launched a retail equity offer via the Winterflood Retail Access Platform to raise up to £1.5 million by issuing 25 million new ordinary shares at 6 pence each, matching the price of a separate £7.5 million institutional subscription announced the same day. The combined fundraising, which is subject to shareholder approval and AIM admission in early April, aims to give U.K. retail investors parity of access while expanding the company’s capital base, though it will dilute existing holdings and remains contingent on the success of the larger subscription.

The WRAP retail offer, open only to eligible U.K. investors through participating intermediaries, carries a minimum subscription of £100 and is expected to close on 20 March with results due around 23 March. By using regulatory exemptions to avoid publishing a full prospectus, ImmuPharma is opting for a quicker, lower‑cost capital raise, but investors are explicitly warned that the shares are high‑risk, may result in total loss of capital, and are not being marketed outside the United Kingdom.

The most recent analyst rating on (GB:IMM) stock is a Sell with a £6.00 price target. To see the full list of analyst forecasts on ImmuPharma stock, see the GB:IMM Stock Forecast page.

ImmuPharma raises up to £7.5m to fast‑track Kapiglucagon as P140 licensing talks advance

ImmuPharma has secured a £6 million equity subscription from long‑term investor Lanstead Capital at 6 pence per share, with a further £1.5 million to be offered via a UK retail WRAP offer, to accelerate development of Kapiglucagon for Type 1 diabetes. The company says proceeds, deployed through an FDA 505(b)(2) route, extend its cash runway to at least the second half of 2028 and allow it to advance Kapiglucagon as a component of dual‑hormone artificial pancreas devices, while maintaining P140 as its core value driver.

Management reports that P140 has made significant progress, including a patent filing in 2025, and expects to secure a licensing agreement in 2026, which could further de‑risk the business. The Lanstead arrangement, structured via a 20‑month sharing agreement, links monthly cash receipts to ImmuPharma’s share price, giving the company potential upside from positive newsflow on both P140 and Kapiglucagon but introducing variability in funding outcomes for shareholders.

The most recent analyst rating on (GB:IMM) stock is a Sell with a £6.00 price target. To see the full list of analyst forecasts on ImmuPharma stock, see the GB:IMM Stock Forecast page.

ImmuPharma Targets Investor Visibility at JP Morgan Conference and Biotech Showcase

ImmuPharma announced that its senior leadership team, including the CEO, COO and CSO, will attend the JP Morgan Healthcare Conference and the Biotech Showcase in San Francisco from 12–14 January 2026. Participation in these high-profile investor and partnering events is intended to strengthen the company’s visibility among global biopharma companies and investors, potentially supporting future strategic collaborations and funding opportunities.

The most recent analyst rating on (GB:IMM) stock is a Hold with a £6.00 price target. To see the full list of analyst forecasts on ImmuPharma stock, see the GB:IMM Stock Forecast page.